A new study suggests that never-seen-before stem cells in the human retina can restore vision in mice with a common eye ...

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...

Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.  The funding will be used ...

To apply a precision medicine approach to this disease, Character Bio has partnered with over 150 ophthalmology treatment ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Researchers identified in a new study that exposure to heavy air pollution, especially particulate matter (PM10), is strongly ...

We don’t know who first said that the eye is the window to the soul, but if they were around today, they might well phrase it ...

Co-led by new investors aMoon and Luma Group, Bausch + Lomb, Jefferson Life Sciences and others also participated in the funding, which will accelerate the advancement of pipeline precision therapies ...

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

In an era where screens dominate our daily lives, a silent epidemic is sweeping the globe. Digital eye strain, a condition ...